Abstract Library

#2287 Mitochondrial or Aerobic Glycolysis Oriented Metabolism May Define Pancreatic Neuroendocrine Tumors (PanNET) Resistance to mTOR-Targeting Therapies

Introduction: The mTOR inhibitor Everolimus is approved for the treatment of PanNET and no predictive biomarker is available. mTOR is a central node controlling mitochondrial and aerobic glycolytic metabolisms.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Cros J, Bucau M, Raffenne J, Soukeur M, Dumont F,

Keywords: mTOR, everolimus, pancreatic NET, metabolism,

#2108 Molecular Characterization of Primary and Metastatic Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumours (PNETs) are a heterogeneous group of rare pancreatic neoplasms often diagnosed with distant metastases, which are associated with significantly poorer prognosis. Recurrent somatic mutations, chromosomal aberrations and gene expression signatures in PNETs have been described, but the clinical significance of these molecular changes is still poorly understood, and the clinical outcomes of PNET patients remain highly variable.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Yang K, Wong H, Shen Y, Colborne S, Kalloger S,

Keywords: pancreatic neuroendocrine tumor, metastasis, primary tumor, proteomics, transcriptomics,

#1564 Well Differentiated Pancreatic Neuroendocrine Tumors (WDPNET) G3: Does the Ki67 Really Do It All?

Introduction: WDPNET G3, although not recognized by the 2010 WHO classification are far from exceptional. They also represent a great therapeutic challenge especially since their molecular drivers are unknown.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: JEROME C

Authors: Cros J, Soukeur M, Raffenne J, Florent D, Thomas De Montpreville V,

Keywords: G3 PNET, transcriptomic profiles, NEC,

#1557 Dual High Throughput Proteomic and Transcriptomic Screen for Predictive Biomarkers of Everolimus Sensitivity in Pancreatic NET

Introduction: mTOR inhibitor Everolimus is approved for the treatment of well-differentiated PNET. The heterogeneity of the response rate and the potential toxicity warrant predictive biomarkers.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: CROS J

Authors: Bucau M, Cros J, Raffenne J, Rebours V, Palazzo M,

Keywords: PNET, everolimus, predictive biomarkers,